Prelude therapeutics presents preliminary results of phase 1 dose-escalation study of prt2527 as monotherapy and in combination with zanubrutinib in patients with relapsed/refractory lymphoid malignancies

• prt2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior car-t therapy

PRLD Ratings Summary

PRLD Quant Ranking